HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
IBRX
ImmunityBio Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $8.19B
Market Cap
$8.19B
Enterprise Val
$8.94B
P/E Ratio
-9.59
P/B Ratio
-9.42
Trailing PEG (1Y)
-0.03
As Of
May 14, 2026

Overview & Key Metrics

Reporting period: Mar 31, 2026 · Q1 2026
Book Value-$869.1M
Gross Margin99.46%
Profit Margin99.46%
Return on Equity138.64%
Return on Assets-165.16%
Current Ratio6.67
Debt/Equity-1.29
LT Debt/Equity-1.28
Revenue Per Share0.04

Income Statement

Mar 31, 2026
Revenue$44.2M
Cost of Revenue$238.0K
Gross Profit$44.0M
R&D$68.0M
SG&A$45.8M
Operating Expenses$113.8M
Operating Income-$69.8M
Interest Expense$28.5M
Tax Expense$9.0K
Net Income-$632.8M
EPS (Basic)$-0.62
EPS (Diluted)$-0.62
EBIT-$604.3M
EBITDA-$598.2M
Consolidated Income-$632.8M
Non-Controlling Interests-$15.0K

Balance Sheet

Mar 31, 2026
Cash & Equivalents$205.2M
Accounts Receivable$43.3M
Inventory$19.4M
Current Assets$453.0M
LT Investments$0.00
Property, Plant & Equipment$145.8M
Intangibles$12.9M
Non-Current Assets$193.7M
Total Assets$646.6M
Accounts Payable$12.1M
Current Debt$7.6M
Current Liabilities$68.0M
LT Debt$1.12B
Non-Current Liabilities$1.45B
Total Liabilities$1.52B
Total Debt$1.12B
Retained Earnings-$4.36B
Shareholder Equity-$870.0M
Shares Outstanding1,028,111,456

Cash Flow Statement

Mar 31, 2026
Operating Cash Flow-$75.4M
Investing Cash Flow-$31.7M
Financing Cash Flow$223.9M
CapEx-$1.8M
Free Cash Flow-$77.1M
Depreciation & Amort.$6.1M
Stock-Based Comp$8.2M
Acquisitions / Disposals$0.00
Investment Activity-$29.9M
Debt Issued/Repaid-$820.0K
Equity Issued/Repaid$149.7M
Dividends Paid$0.00
Net Change in Cash$117.0M
Data cached · Meta live · Daily live · Statements live · TTL 24h